Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Malignant Lymphoma

Free Subscription 16.03.2026 4 Am J Hematol 1 Am J Pathol 1 Am J Surg Pathol 1 Biochem Biophys Res Commun 2 Blood 1 Bone Marrow Transplant 9 Br J Haematol 1 Cancer 3 Eur J Haematol 4 Haematologica 1 Hum Pathol 5 Leuk Lymphoma 2 Leukemia 2 Mod Pathol 1 Mol Ther Oncol 2 Oncology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. MANAKOV D, Klanova M, Kolar M, Ivanek R, et al
   Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment-Resistant Subclones at the Time of Diagnosis.
   Am J Hematol. 2026 Mar 9. doi: 10.1002/ajh.70270.
   PubMed         Abstract available
   
   
2. TAVAKKOLI M, Barta SK
   2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
   Am J Hematol. 2023;98:1791-1805.
   PubMed         Abstract available
   
   
3. DENG L, Li Z, Zhang H, Huang H, et al
   Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
   Am J Hematol. 2023;98:1742-1750.
   PubMed         Abstract available
   
   
4. HAN F, Zhong Y, Tong C, Wang C, et al
   Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.
   Am J Hematol. 2026 Mar 9. doi: 10.1002/ajh.70281.
   PubMed         Abstract available
   
   

   
   Am J Pathol

5. ZHANG I, Chalise S, Roshal M, Gao Q, et al
   Leveraging Kappa-Lambda Signatures in a Multi-Stage Machine Learning Pipeline for B-Cell Lymphoma Detection by Flow Cytometry.
   Am J Pathol. 2026 Mar 5:S0002-9440(26)00058-1. doi: 10.1016/j.ajpath.2026.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

6. HELMAN SR, Merechi F, Alharthy H, Koka R, et al
   Comprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma.
   Am J Surg Pathol. 2026 Mar 10. doi: 10.1097/PAS.0000000000002519.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

7. YANG H, Liu Y, Yang J, Zhang Q, et al
   Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2.
   Biochem Biophys Res Commun. 2023;676:21-29.
   PubMed         Abstract available
   
   

   
   Blood

8. RHEIN S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, et al
   A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.
   Blood. 2026;147:1058-1069.
   PubMed         Abstract available
   
   
9. FELDMAN AL, Dasari S, Rimsza LM, Scott DW, et al
   Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.
   Blood. 2026;147:1199-1214.
   PubMed         Abstract available
   
   

   
   Bone Marrow Transplant

10. FACCHIN G, Battista ML, Olivieri J, Pasquale R, et al
    Bispecific antibodies followed by allogeneic hematopoietic stem cell transplantation as rescue therapy in refractory/relapsed B cell non-Hodgkin lymphoma: a real-life experience.
    Bone Marrow Transplant. 2026 Mar 9. doi: 10.1038/s41409-026-02812.
    PubMed        
    
    

    
    Br J Haematol

11. WATANABE M, Kanda J, Fukuda T, Uchida N, et al
    Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.
    Br J Haematol. 2023;203:446-459.
    PubMed         Abstract available
    
    
12. O'REILLY MA, Wilson W, Maybury B, Kuhnl A, et al
    Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.
    Br J Haematol. 2026 Mar 8. doi: 10.1111/bjh.70357.
    PubMed         Abstract available
    
    
13. LIM MS
    Haematolymphoid malignancies: It is not important WHO we are but WHERE we go from here.
    Br J Haematol. 2023;203:349-350.
    PubMed         Abstract available
    
    
14. CHUNG EYL, Sartori G, Ponzoni M, Cascione L, et al
    ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.
    Br J Haematol. 2023;203:244-254.
    PubMed         Abstract available
    
    
15. FALINI B, Lazzi S, Pileri S
    A comparison of the International Consensus and 5th WHO classifications of T-cell lymphomas and histiocytic/dendritic cell tumours.
    Br J Haematol. 2023;203:369-383.
    PubMed         Abstract available
    
    
16. DE RE V, Lopci E, Brisotto G, Elia C, et al
    Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.
    Br J Haematol. 2026 Mar 12. doi: 10.1111/bjh.70423.
    PubMed         Abstract available
    
    
17. CHOLACK GA, Mwangi R, Vodicka P, Habermann TM, et al
    Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.
    Br J Haematol. 2026 Mar 10. doi: 10.1111/bjh.70397.
    PubMed         Abstract available
    
    
18. RIGOLIN GM, Soddu S, Dondolin R, Frustaci AM, et al
    Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA wo
    Br J Haematol. 2026 Mar 10. doi: 10.1111/bjh.70401.
    PubMed        
    
    
19. NASIBOV T, Cunningham A, Sarpong L, Smyth E, et al
    Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.
    Br J Haematol. 2026 Mar 10. doi: 10.1111/bjh.70417.
    PubMed        
    
    

    
    Cancer

20. WADHWA A, Lim S, Dai C, Daniels G, et al
    Assessment of longitudinal changes in body composition of children with lymphoma and rhabdomyosarcoma.
    Cancer. 2023;129:3457-3465.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

21. RIBATTI D
    Endothelial Cells in Lymphomas.
    Eur J Haematol. 2026;116:350-356.
    PubMed         Abstract available
    
    
22. MOTMAEN I, Sereda S, Brobeil A, Shankar A, et al
    Deep-learning based classification of a tumor marker for prognosis on Hodgkin's disease.
    Eur J Haematol. 2023;111:722-728.
    PubMed         Abstract available
    
    
23. CASERTA S, Martino EA, Skafi M, Alvaro ME, et al
    Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.
    Eur J Haematol. 2026 Mar 7. doi: 10.1111/ejh.70153.
    PubMed         Abstract available
    
    

    
    Haematologica

24. NOERENBERG D
    Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma.
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2026.300488.
    PubMed         Abstract available
    
    
25. AVIVI I
    Unmasking the invisible: CAR T-cell therapy for intravascular large B-cell lymphoma.
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2026.300761.
    PubMed         Abstract available
    
    
26. RUSSLER-GERMAIN DA, Bartlett NL
    To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2026.300832.
    PubMed         Abstract available
    
    
27. PICARDI M, Vincenzi A
    Systematic echocardiogram surveillance to early detect and treat doxorubicin hydrochloride-induced cardiomyopathy in young adults and adults with classical Hodgkin lymphoma. Comment on: Long-term cardiac morbidity in adolescent and young adult survivo
    Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2025.300167.
    PubMed         Abstract available
    
    

    
    Hum Pathol

28. SALEH JS, Subtil A, Hristov AC
    Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.
    Hum Pathol. 2023;138:76-102.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

29. HAO X, Zhang J, Liu S, Luo L, et al
    Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.
    Leuk Lymphoma. 2026 Mar 7:1-9. doi: 10.1080/10428194.2026.2637864.
    PubMed         Abstract available
    
    
30. GOKHALE M, Chan PK, Jiang W, Levin R, et al
    Healthcare resource utilization, costs, and survival among Medicare beneficiaries with relapsed or refractory DLBCL receiving second-line therapy: a real-world evidence study.
    Leuk Lymphoma. 2026;67:582-591.
    PubMed         Abstract available
    
    
31. BHABHA F, Prince HM, Campbell B, Van Der Weyden C, et al
    Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.
    Leuk Lymphoma. 2026;67:536-555.
    PubMed         Abstract available
    
    
32. GUOLO F, Del Sette P, Riccardi F, Ballerini F, et al
    Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications.
    Leuk Lymphoma. 2026 Mar 7:1-7. doi: 10.1080/10428194.2026.2634180.
    PubMed         Abstract available
    
    
33. KYVSGAARD ER, Fuglkjaer AD, Al-Mashhadi AL, Hasselbalch Riley C, et al
    A real-world comparison of CD20xCD3 bispecific antibodies versus chemotherapy regimens in 3+ line relapsed/refractory diffuse large B cell lymphoma.
    Leuk Lymphoma. 2026 Mar 11:1-5. doi: 10.1080/10428194.2026.2637858.
    PubMed        
    
    

    
    Leukemia

34. GRUNENBERG A, Schmelzle B, Gokeler J, Mund H, et al
    Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.
    Leukemia. 2026 Mar 6. doi: 10.1038/s41375-026-02869.
    PubMed        
    
    
35. LONARDI S, Cancila V, Morello G, Varano G, et al
    RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.
    Leukemia. 2026 Mar 6. doi: 10.1038/s41375-026-02896.
    PubMed        
    
    

    
    Mod Pathol

36. YOUNES S, Zhao S, Bharadwaj S, Mosquera AP, et al
    Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.
    Mod Pathol. 2023;36:100256.
    PubMed         Abstract available
    
    
37. SAKAMOTO K, Baba S, Okumura Y, Momose S, et al
    Comparison and Development of Immunohistochemical Diagnostic Criteria for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Mod Pathol. 2023;36:100253.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

38. NGUYEN LT, Nguyen DD, Bach QK, Dao LTM, et al
    Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in Vietnam.
    Mol Ther Oncol. 2026;34:201156.
    PubMed         Abstract available
    
    

    
    Oncology

39. ZHANG J, Liu S
    The Impact of Surgical Intervention on The Survival of Primary Head and Neck MALT Lymphoma.
    Oncology. 2026 Mar 10:1-21. doi: 10.1159/000551044.
    PubMed         Abstract available
    
    
40. YUCEL OK, Vural E, Alhan N, Vurgun S, et al
    Lower Body Mass Index and Prognostic Nutritional Index Are Associated with Poor Posttransplant Outcomes in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Oncology. 2023;101:753-764.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum